B-cell lymphoma 2

Overview

B-cell lymphoma 2 (BCL2) is a critical anti-apoptotic protein that plays a significant role in regulating cell death and survival. It is part of the Bcl-2 family of proteins, which are integral to the intrinsic pathway of apoptosis, a process essential for maintaining cellular homeostasis and tissue integrity. BCL2 functions by inhibiting the activation of pro-apoptotic factors, thereby preventing apoptosis in response to various cellular stressors. Its overexpression is frequently associated with several malignancies, including chronic lymphocytic leukemia and various solid tumors, making it a significant target for cancer therapies, particularly in the context of Targeted therapies like the venetoclax.

Focus of Latest Publications

Recent publications have continued to position B-cell lymphoma 2 (BCL2) as a central anti-apoptotic target across diverse cancer and disease models. Several studies evaluated BCL2 in combination with other pathway inhibitors or as part of multi-target therapeutic strategies. In acute myeloid leukemia, BCL2 inhibition was examined alongside PI3Kδ blockade, gemtuzumab ozogamicin, and venetoclax-based combinations, with reports of enhanced apoptosis, improved cytotoxicity, or synergistic effects in selected cell lines. In myelofibrosis, navitoclax, a BCL-XL/BCL-2 inhibitor, was combined with ruxolitinib and showed clinically meaningful activity in a phase 2 cohort. In castration-resistant prostate cancer, single-cell imaging, preclinical models, and a phase Ib trial supported BCL2 as a shared vulnerability, with venetoclax plus enzalutamide reducing circulating tumor cells in responding patients. A review on lymphoma therapies also highlighted BCL2-pathway targeting as a major component of the current precision-medicine landscape.

Other studies focused on natural products, engineered biomolecules, or computational screening approaches that implicated BCL2 in apoptosis regulation. Tetrahydroberberine was reported to bind and stabilize the bcl-2 promoter G-quadruplex, suppressing nasopharyngeal carcinoma cell proliferation and activating mitochondrial apoptosis through the Bax/bcl-2/caspase-3 axis. Nobiletin was described as a natural BH3 mimetic that downregulated BCL-2 and MCL-1 in non-small cell lung cancer cells, while also disrupting the Beclin-1/BCL-2 complex. berberine chloride, garlic-derived organosulfur compounds, and a nutraceutical polyherbal formulation were each assessed by docking or network pharmacology and were predicted to interact with BCL2 among other cancer-related targets. In hepatocellular carcinoma, a sophocarpine-derived compound was designed as a putative dual Bcl-2/Mcl-1 inhibitor and induced apoptosis with downregulation of both proteins. Similarly, an SN-38-nitrogen mustard conjugate reduced Bcl-2 protein levels and activated caspase-3 in tumor models.

BCL2 was also studied outside oncology in contexts where apoptosis, inflammation, or tissue injury were relevant. In a rat model of chronic stress-induced testicular damage, Ashwagandha increased Bcl-2 immunoreactivity and improved the Bax/Bcl-2 ratio. In ischemic stroke and cerebral ischemia-reperfusion injury models, poliumoside and eupalinolide B were reported to regulate Bcl-2 alongside oxidative stress and mitochondrial pathways. In diabetic neuroinflammation, FuBIG upregulated Bcl-2 while reducing Bax and caspase-3. In calcific aortic valve disease, engineered exosomes overexpressing bcl2 reduced apoptosis in cardiomyocytes and valve interstitial cells. In colorectal cancer, exosomal miR-21-5p was shown to suppress HRK, thereby relieving inhibition of Bcl-2 and promoting malignant progression. Across these studies, BCL2 repeatedly emerged as a marker and mediator of cell survival, with recent work emphasizing its value as a therapeutic target and as a node within broader apoptosis- and mitochondria-related signaling networks.